NASDAQ: TGTX
Healthcare · Biotechnology
Market Cap
$5.70B
52w High
$40.99
52w Low
$25.28
P/E
11.41
Volume
1.92M
Outstanding Shares
159.69M
Price vs Fundamentals
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
The stock fell 5.23% over the last year. Revenue grew 87.32% over the trailing twelve months. Operating margin moved from 12.74% to 20.01%. Free cash flow grew 38.4% over the trailing twelve months.
The stock has moved lower against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
Operating margin currently stands at 20.01%. A decisive move in revenue — currently up 87.32% — would be the clearest signal to resolve the ambiguity.
Company profile
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
Valuation
Stock splits
Every 225 shares became 4
Every 50 shares became 1
Every 5 shares became 1
Profitability & growth
Analyst consensus
11
Buy
1
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 6, 2026
Q2 FY26 · EPS est $0.23 · Revenue est $200.33M
View